Literature DB >> 17014519

Prognostic implications of clinical practice guidelines among hemodialysis patients.

John J Chang1, John Concato, Carolyn K Wells, Susan T Crowley.   

Abstract

Although the National Kidney Foundation (NKF) has published clinical practice guidelines for the management of risk factors for cardiovascular disease, these guidelines have not been tested rigorously for their effectiveness. We conducted an observational study among patients with end-stage kidney disease to examine the prognostic impact of threshold levels recommended by the NKF for blood pressure, hemoglobin, calcium-phosphate product, parathyroid hormone, low-density lipoprotein, and glycosylated hemoglobin. The study population (N = 197) was assembled from a previously completed randomized trial examining arteriovenous graft thrombosis. Cox proportional hazard analysis was used to calculate hazard ratios for the association of levels outside guideline recommended targets and death, adjusting for age, comorbidity, race, and albumin. The proportion of patients outside guideline targets ranged from 33% to 81%, and the impact of levels outside guideline targets on mortality varied substantially. Elevated calcium-phosphate product and glycosylated hemoglobin had harmful effects, with adjusted hazard ratios of 1.58 (95% CI 1.00-2.50; p = 0.050) and 2.21 (95% CI 0.99-4.97; p = 0.054), respectively. Nontarget levels for blood pressure, hemoglobin, and parathyroid hormone had little effect, with adjusted hazard ratios of 1.15 (95% CI 0.74-1.78; p = 0.542), 1.04 (95% CI 0.65-1.68; p = 0.866), and 0.90 (95% CI 0.50-1.61; p = 0.722), respectively. Elevated low-density lipoprotein had a paradoxically beneficial effect, with an adjusted hazard ratio of 0.48 (95% CI 0.23-1.00; p = 0.049). These results suggest that the prognostic impact of current threshold levels recommended by select NKF guidelines on mortality is variable. Accordingly, the development and implementation of clinical practice guidelines should be accompanied by corresponding efforts to confirm their impact on patient outcomes. Such efforts are essential for the improvement of guidelines and to inform health policy optimally.

Entities:  

Mesh:

Year:  2006        PMID: 17014519     DOI: 10.1111/j.1542-4758.2006.00137.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  2 in total

1.  Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure.

Authors:  Richard M Cubbon; Ceri Haf Thomas; Michael Drozd; John Gierula; Haqeel A Jamil; Rowenna Byrom; Julian H Barth; Mark T Kearney; Klaus K A Witte
Journal:  J Nephrol       Date:  2014-03-11       Impact factor: 3.902

Review 2.  Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis.

Authors:  Jaime L Natoli; Rob Boer; Brian H Nathanson; Ross M Miller; Silvia Chiroli; William G Goodman; Vasily Belozeroff
Journal:  BMC Nephrol       Date:  2013-04-17       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.